abiraterone-acetate and Leukemia--Myeloid--Acute

We present the case of a 70-year-old patient affected by metastatic castration-resistant prostate cancer. He underwent radical prostatectomy in 2007 and subsequent adjuvant radiotherapy and hormonal therapy for 2 years. In 2011, he developed bilateral lung metastases, and therefore he received chemotherapy (eight cycles of docetaxel 75 mg/sqm every 3 weeks) with partial remission; rechallenge with the same drug was performed 7 months later due to recurrence of lung metastases. In August 2013, abiraterone acetate was started for progression of lung metastases. The patient received abiraterone for almost 5 years with stability of disease. During the 60th cycle of abiraterone, a diagnosis of acute myeloid leukemia was made.

Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Disease Progression; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome